Courtney V Fletcher
Overview
Explore the profile of Courtney V Fletcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
3901
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luetkemeyer A, Chew K, Lacey S, Hughes M, Harrison L, Daar E, et al.
Clin Infect Dis
. 2025 Feb;
PMID: 39960062
Background: Ensitrelvir, a severe acute respiratory syndrome coronavirus-2 main protease inhibitor, has demonstrated clinical and virologic efficacy in previous studies. Methods: In this global phase 3 trial, nonhospitalized adults with...
2.
Webb G, Sauter K, Takahashi D, Kirigiti M, Bader L, Lindsley S, et al.
JCI Insight
. 2024 Aug;
9(18).
PMID: 39115937
Current antiretroviral therapy (ART) regimens efficiently limit HIV replication, thereby improving the life expectancy of people living with HIV; however, they also cause metabolic side effects. The ongoing obesity epidemic...
3.
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial
Chew K, Taiwo B, Moser C, Daar E, Wohl D, Ritz J, et al.
J Infect Dis
. 2024 Jul;
230(5):1177-1186.
PMID: 39028902
Background: We evaluated the fully human polyclonal antibody product SAB-185 in a phase 3 trial for COVID-19. Methods: Nonhospitalized high-risk adults within 7 days of symptom onset were randomized 1:1...
4.
Malik J, Modebelu U, Fletcher C, Podany A, Scarsi K, Byrareddy S, et al.
Curr Protoc
. 2024 Jun;
4(6):e1067.
PMID: 38857108
The blood-brain barrier (BBB) constitutes a crucial protective anatomical layer with a microenvironment that tightly controls material transit. Constructing an in vitro BBB model to replicate in vivo features requires...
5.
Corado K, Chew K, Giganti M, Mu Y, Fletcher C, Currier J, et al.
Pathog Immun
. 2024 May;
9(1):138-155.
PMID: 38746756
Background: Outpatient COVID-19 monoclonal antibody (mAb) treatment via subcutaneous delivery, if effective, overcomes the logistical burdens of intravenous administration. Methods: ACTIV-2/A5401 was a randomized, masked placebo-controlled platform trial where participants...
6.
Avedissian S, Malik J, Podany A, Neely M, Rhodes N, Scarsi K, et al.
Sci Rep
. 2024 May;
14(1):10709.
PMID: 38729980
Three years after SARS-CoV-2 emerged as a global infectious threat, the virus has become endemic. The neurological complications such as depression, anxiety, and other CNS complications after COVID-19 disease are...
7.
Zhou X, Horga A, Puri A, Winchester L, Montrond M, Pietropaolo K, et al.
J Antimicrob Chemother
. 2024 May;
79(6):1423-1431.
PMID: 38708557
Background: Bemnifosbuvir (AT-527) is a novel oral guanosine nucleotide antiviral drug for the treatment of persons with COVID-19. Direct assessment of drug disposition in the lungs, via bronchoalveolar lavage, is...
8.
Malik J, Podany A, Khan P, Shaffer C, Siddiqui J, Baranowska-Kortylewicz J, et al.
Cancer Med
. 2023 Nov;
12(23):21075-21096.
PMID: 37997517
Background: Pediatric brain tumors (PBT) stand as the leading cause of cancer-related deaths in children. Chemoradiation protocols have improved survival rates, even for non-resectable tumors. Nonetheless, radiation therapy carries the...
9.
Jagannathan P, Chew K, Giganti M, Hughes M, Moser C, Main M, et al.
EClinicalMedicine
. 2023 Oct;
65:102250.
PMID: 37855026
Background: With the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited global access to therapeutics, the evaluation of novel therapeutics to prevent progression to severe COVID-19 remains...
10.
Harwood O, Matschke L, Moriarty R, Balgeman A, Weaver A, Ellis-Connell A, et al.
PLoS Pathog
. 2023 Sep;
19(9):e1011676.
PMID: 37747933
Sustainable HIV remission after antiretroviral therapy (ART) withdrawal, or post-treatment control (PTC), remains a top priority for HIV treatment. We observed surprising PTC in an MHC-haplomatched cohort of MHC-M3+ SIVmac239+...